Patents Examined by Ileana Popa
  • Patent number: 11534493
    Abstract: The low aqueous solubility of roflumilast in parenteral preparations and topical emulsions, suspensions, gels or solutions can be improved by including a blend of water-miscible solvents in the pharmaceutical composition. The blend of water-miscible solvents can include diethylene glycol monoethyl ether (Tradename Transcutol®; abbreviated DEGEE) and water. The ratio of diethylene glycol monoethyl ether to water is from 1:10 to 20:1. The resulting composition has improved bioavailability and efficacy and can be used to inhibit phosphodiesterase 4 in a patient in need of such treatment.
    Type: Grant
    Filed: September 22, 2017
    Date of Patent: December 27, 2022
    Assignee: Arcutis Biotherapeutics, Inc.
    Inventor: David W. Osborne
  • Patent number: 11529396
    Abstract: The invention provides compositions and methods useful for the treatment and prevention of conditions associated with short telomere length.
    Type: Grant
    Filed: August 4, 2015
    Date of Patent: December 20, 2022
    Assignees: FUNDACIÓN DEL SECTOR PÚBLICO ESTATAL CENTRO NACIONAL DL'INVESTIGACIONES ONCOLÓGICAS CARLOS III (F.S.P. CNIO), UNIVERSITAT AUTÓNOMA DE BARCELONA
    Inventors: Maria Bobadilla, Ivan Formentini, Maria Antonia Blasco Marhuenda, Christian Baer, Fàtima Bosch I Tubert
  • Patent number: 11484558
    Abstract: The present invention relates to a unique oncolytic virus, Epizootic Hemorrhagic Disease virus-Tel Aviv University (EHDV-TAU), and to methods and pharmaceutical compositions comprising thereof for preventing or treating cancer exhibiting an alteration in interferon signaling and/or the innate immune antiviral response.
    Type: Grant
    Filed: June 26, 2018
    Date of Patent: November 1, 2022
    Assignee: RAMOT AT TEL-AVIV UNIVERSITY LTD
    Inventors: Marcelo Ehrlich, Eran Bacharach, Ben Shai, Oded Danziger
  • Patent number: 11478518
    Abstract: The present invention relates to oncolytic vaccinia viruses which have been modified to promote anti-tumor immunity and/or reduce host immunity and/or antibody response against the virus. It is based, at least in part, on the discovery that oncolytic vaccinia virus (i) bearing a genome deletion of a gene that reduces T cell immunity (interleukin-18 binding protein); (ii) treated with a sialidase enzyme which is believed to reduce TLR2 activation and therefore the antibody response; (iii) carrying a gene that enhances cytotoxic T lymphocyte induction (e.g., TRIF) and/or (iv) reduces tumor myeloid-derived suppressor cells by reducing prostaglandin E2 reduces tumor growth. Accordingly, the present invention provides for immunooncolytic vaccinia viruses and methods of using them in the treatment of cancers.
    Type: Grant
    Filed: February 19, 2016
    Date of Patent: October 25, 2022
    Assignee: UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventor: Stephen Howard Thorne
  • Patent number: 11446344
    Abstract: This invention relates generally to viral vectors and viral particles based on Anelloviruses, which can be used to deliver an agent (e.g., an exogenous effector or an endogenous effector, e.g., a therapeutic effector) to a cell (e.g., a cell in a subject to be treated therapeutically). Described herein are anellosomes, anellovectors, and compositions and uses thereof.
    Type: Grant
    Filed: September 29, 2021
    Date of Patent: September 20, 2022
    Assignee: FLAGSHIP PIONEERING INNOVATIONS V, INC.
    Inventors: Simon Delagrave, Fernando Martin Diaz, Avak Kahvejian, Kevin James Lebo, Dhananjay Maniklal Nawandar, Jared David Pitts, Ryan D. Tedstone, Erica Gabrielle Weinstein, Nathan Lawrence Yozwiak
  • Patent number: 11446227
    Abstract: The present invention provides a method for preparing an high internal phase of pumpkin seed protein nanoparticles, including dissolving pumpkin seed protein powder in water and adjusting pH to approximately 8 to 11 to obtain a pumpkin seed protein solution; adding the pumpkin seed protein solution through a peristaltic pump into an ethanol solution with stirring for 4 hours to obtain a first solution; performing a centrifugation to the first solution and collecting precipitates; diluting the precipitates with water and performing a freeze-drying to obtain the pumpkin seed protein nanoparticles. The present invention first uses an anti-solvent method to prepare pumpkin seed protein nanoparticles, which have excellent emulsifying properties and can stabilize the high internal phase emulsion. In addition, the resulting pumpkin seed protein nanoparticles can stabilize the high internal phase emulsion independently without compounding with other substances.
    Type: Grant
    Filed: December 2, 2020
    Date of Patent: September 20, 2022
    Assignee: Jiangnan University
    Inventors: Jing Wang, Yongqiang Shen, Cheng Yang, Guangqun Cao
  • Patent number: 11413236
    Abstract: The invention discloses an eyelash liquid eyeliner, wherein the raw materials comprise the following components in parts by weight: 50-60 parts of ethyl hexyl acrylate copolymer, 30-40 natural beeswax, 10-12 carnauba wax, 8-12 polyvinylpyrrolidone, 5-7 shellac, 1-3 black talc powder, 20-30 polyvinyl alcohol, 20-30 of silicone resins, 10-12 of codariocalyx motorius saponin extract, 5-7 dual-directional regulation growth promotion factors, 1-3 antifreeze, 1-3 coloring agent, 1-3 preservative, and 5-7 antioxidant. Components in the liquid eyeliner are replaced with natural substances of the natural beeswax, the carnauba wax, the shellac and the like, and the eyelash liquid eyeliner is safe to skin. Besides, organic silicone resins are added, so that the condition that the eyelash liquid eyeliner is broken up when being in contact with water can be effectively avoided, the organic silicone resin can effectively block ultraviolet rays and prevent the ultraviolet rays from destroying roots of eyelashes.
    Type: Grant
    Filed: December 30, 2020
    Date of Patent: August 16, 2022
    Assignee: Qingdao AJLEJSHJ FALSE EYELASH CO., LTD.
    Inventor: Wengang Guan
  • Patent number: 11407786
    Abstract: A nanosized complex includes siRNA and a compound comprising formula (I):
    Type: Grant
    Filed: September 30, 2019
    Date of Patent: August 9, 2022
    Assignee: CASE WESTERN RESERVE UNIVERSITY
    Inventors: Zheng-Rong Lu, Amita M. Vaidya
  • Patent number: 11400134
    Abstract: Embodiments relate to peptide antagonists of ?c-family cytokines, which is associated with important human diseases, such as leukemia, autoimmune diseases, collagen diseases, diabetes mellitus, skin diseases, degenerative neuronal diseases and graft-versus-host disease (GvHD). Thus, inhibitors of ?c-cytokine activity are valuable therapeutic and cosmetic agents as well as research tools. Traditional approaches to inhibiting yc-cytokine activity involve raising neutralizing antibodies against each individual ?c-cytokine family member/? receptor subunit. However, success has been limited and often multiple ?c-cytokine family members co-operate to cause the disease state. Combinatorial use of neutralizing antibodies raised against each factor is impractical and poses an increased risk of adverse immune reactions. The present embodiments overcome these shortcomings by utilizing peptide antagonists based on the consensus ?c-subunit binding site to inhibit ?c-cytokine activity.
    Type: Grant
    Filed: October 6, 2016
    Date of Patent: August 2, 2022
    Assignee: BIONIZ, LLC
    Inventor: Nazli Azimi
  • Patent number: 11376329
    Abstract: The present disclosure provides certain silk-fibroin compositions with particular characteristics and/or properties. In some embodiments, the disclosure provides low molecular weight compositions. In some embodiments, the disclosure provides silk fibroin compositions that comprise an active (e.g., a biological) agent or component. In some embodiments, the disclosure provides low molecular weight silk fibroin compositions that comprise an active (e.g., a biological) agent or component. In some embodiments, an active agent is stabilized in a silk composition, e.g., for a period of time and/or against certain conditions or events. In some embodiments, a component present in a silk fibroin composition may be subject to analysis and/or characterization. In some embodiments, a component present in a silk fibroin composition may be recovered from the composition.
    Type: Grant
    Filed: March 11, 2016
    Date of Patent: July 5, 2022
    Assignee: Trustees of Tufts College
    Inventors: Jonathan A. Kluge, Fiorenzo G. Omenetto, David L. Kaplan
  • Patent number: 11352631
    Abstract: Disclosed herein are methods and compositions for inactivating TCR genes, using engineered nucleases comprising at least one DNA binding domain and a cleavage domain or cleavage half-domain in conditions able to preserve cell viability. Polynucleotides encoding nucleases, vectors comprising polynucleotides encoding nucleases and cells comprising polynucleotides encoding nucleases and/or cells comprising nucleases are also provided. Disclosed herein are also methods and compositions for expressing a functional exogenous TCR in the absence of endogenous TCR expression in T lymphocytes, including lymphocytes with a central memory phenotype. Polynucleotides encoding exogenous TCR, vectors comprising polynucleotides encoding exogenous TCR and cells comprising polynucleotides encoding exogenous TCR and/or cells comprising exogenous TCR are also provided.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: June 7, 2022
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Gary K. Lee, David Paschon, Lei Zhang
  • Patent number: 11318215
    Abstract: Disclosed herein is a composition for gene delivery which forms into liquid crystals in an aqueous fluid including chitosan and a liquid crystal formation material. The composition of the present invention including chitosan and a liquid crystal formation material improves the relatively low binding strength between chitosan and a gene, and also considerably increases the stability of a chitosan nanocomposite in blood serum, thereby performing highly efficient gene delivery and providing excellent stability, thus being useful as a gene therapeutic agent.
    Type: Grant
    Filed: February 28, 2014
    Date of Patent: May 3, 2022
    Assignee: Chong Kun Dang Pharmaceutical Corp.
    Inventors: Ho Young Hwang, Ji Hye Hwang, Young Nam Lee, Sang Myoung Noh, Min Hyo Ki
  • Patent number: 11306284
    Abstract: Methods for introducing exogenous material into a cell are provided, which include exposing the cell to a transient decrease in pressure in the presence of the exogenous material. Also provided are devices for performing the method of the invention.
    Type: Grant
    Filed: August 9, 2018
    Date of Patent: April 19, 2022
    Inventor: Ryan Pawell
  • Patent number: 11299715
    Abstract: The use of iNOS inhibitors, including aurintricarboxylic acid, dexamethasone and valproic acid, to increase the yield of a variety of viruses in culture, including recombinant herpesviruses is described.
    Type: Grant
    Filed: January 7, 2014
    Date of Patent: April 12, 2022
    Assignee: Genzyme Corporation
    Inventors: Peter Pechan, Jeffery Ardinger, Abraham Scaria, Samuel Wadsworth
  • Patent number: 11268060
    Abstract: Methods for introducing exogenous material into a cell are provided, which include exposing the cell to a transient decrease in pressure in the presence of the exogenous material. Also provided are devices for performing the method of the invention.
    Type: Grant
    Filed: April 25, 2017
    Date of Patent: March 8, 2022
    Inventor: Ryan Pawell
  • Patent number: 11261434
    Abstract: The invention provides compositions and methods useful for the treatment and prevention of conditions associated with myocardial infarction.
    Type: Grant
    Filed: August 4, 2015
    Date of Patent: March 1, 2022
    Assignees: Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO), Universität Autónoma de Barcelona
    Inventors: Maria Antonia Blasco Marhuenda, Bruno Bernardes De Jesus, Christian Baer, Rosa María Serrano Ruiz, Fàtima Bosch I Tubert, Eduard Ayuso, Ivan Formentini, Maria Bobadilla, Jacques Mizrahi
  • Patent number: 11242533
    Abstract: Described herein are immuno-stimulatory RNA nanostructures (which comprises a single-stranded RNA (ssRNA) molecule, wherein the ssRNA molecule forms at least one paranemic cohesion crossover), as well as compositions and methods of use thereof.
    Type: Grant
    Filed: January 10, 2019
    Date of Patent: February 8, 2022
    Assignee: ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY
    Inventors: Yung Chang, Hao Yan, Xiaodong Qi, Fei Zhang
  • Patent number: 11229720
    Abstract: The present invention is directed to hemostatic compositions comprising at least partially integrated agglomerated oxidized regenerated cellulose (ORC) fibers, fibrinogen, and thrombin and methods of forming a powdered hemostatic composition, comprising the steps of: forming a suspension of a mixture comprising particles of fibrinogen, thrombin, ORC fibers in a non-aqueous low boiling solvent; spraying the suspension through a nozzle onto a substrate, allowing the non-aqueous solvent to evaporate; separating from the substrate and sieving the composition.
    Type: Grant
    Filed: September 7, 2016
    Date of Patent: January 25, 2022
    Assignee: Guangzhou Bioseal Biotech Co., Ltd.
    Inventors: Shuang Chen, Yufu Li, Dengmin Feng, Xiang Wan
  • Patent number: 11203627
    Abstract: The present invention relates to T cell receptors (TCRs) which bind the HLA-A*02 restricted peptide GLYDGMEHL (SEQ ID NO: 1) derived from the MAGE-A10 protein. The TCRs of the invention demonstrate excellent specificity profiles for this MAGE epitope. Also provided are nucleic acids encoding the TCRs, cells engineered to present the TCRs, cells harbouring expression vectors encoding the TCRs and pharmaceutical compositions comprising the TCRs, nucleic acids or cells of the invention.
    Type: Grant
    Filed: April 5, 2017
    Date of Patent: December 21, 2021
    Assignee: ADAPTIMMUNE LIMITED
    Inventors: Conor Hayes, Arsen Volkov, Andrew Gerry, Ellen Border, Edward Carter
  • Patent number: 11191786
    Abstract: It was revealed that the intravenous administration of HMGB-1 and S100A8 promoted the healing of skin ulcer by recruiting bone marrow-derived cells to the site of skin ulcer. Furthermore, when HMGB-1 was intravenously administered to cerebral infarction model mice after creation of cerebral infarction, bone marrow-derived cells expressing nerve cell markers were detected in their brain. A marked cerebral infarct-reducing effect was observed in mice intravenously administered with HMGB-1 as compared to the control. The post-cerebral infarction survival rate was increased in the intravenous HMGB-1 administration group. The involvement of bone marrow pluripotent stem cells in the process of bone fracture healing was assessed using mice, and the result demonstrated that bone marrow-derived cells distant from the damaged site migrated to the bone fracture site to repair the damaged tissue.
    Type: Grant
    Filed: October 28, 2010
    Date of Patent: December 7, 2021
    Assignees: STEMRIM INC., OSAKA UNIVERSITY
    Inventors: Katsuto Tamai, Yasufumi Kaneda, Takehiko Yamazaki, Takenao Chino, Kotaro Saga, Mayumi Endo